Avadel Pharmaceuticals PLC reports results for the quarter ended September 30 - Earnings Summary

• Avadel Pharmaceuticals PLC AVDL.OQ reported a quarterly adjusted loss of 3 cents​​ per share for the quarter ended September 30, higher than the same quarter last year, when the company reported EPS of -41 cents. The mean expectation of ten analysts for the quarter was for a loss of 6 cents per share. Wall Street expected results to range from -11 cents to -1 cents per share.

• Revenue rose 613.2% to $50.03 million from a year ago; analysts expected $48.61 million.

• Avadel Pharmaceuticals PLC's reported EPS for the quarter was a loss of 3 cents​.

• The company reported a quarterly loss of $2.63 million.

• Avadel Pharmaceuticals PLC shares had risen by 24.3% this quarter and gained 15.4% so far this year.

FORECAST CHANGES

• The mean earnings estimate of analysts was unchanged in the last three months.​

• In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 10 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."

• The average consensus recommendation for the pharmaceuticals peer group is also "buy"

Wall Street's median 12-month price target for Avadel Pharmaceuticals PLC is 24.00

This summary was machine generated from LSEG data November 12 at 03:39 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)